189 related articles for article (PubMed ID: 19580467)
1. Potential mediators of the mortality reduction with zoledronic acid after hip fracture.
Colón-Emeric CS; Mesenbrink P; Lyles KW; Pieper CF; Boonen S; Delmas P; Eriksen EF; Magaziner J
J Bone Miner Res; 2010 Jan; 25(1):91-7. PubMed ID: 19580467
[TBL] [Abstract][Full Text] [Related]
2. Zoledronic acid and clinical fractures and mortality after hip fracture.
Lyles KW; Colón-Emeric CS; Magaziner JS; Adachi JD; Pieper CF; Mautalen C; Hyldstrup L; Recknor C; Nordsletten L; Moore KA; Lavecchia C; Zhang J; Mesenbrink P; Hodgson PK; Abrams K; Orloff JJ; Horowitz Z; Eriksen EF; Boonen S;
N Engl J Med; 2007 Nov; 357(18):1799-809. PubMed ID: 17878149
[TBL] [Abstract][Full Text] [Related]
3. Association between timing of zoledronic acid infusion and hip fracture healing.
Colón-Emeric C; Nordsletten L; Olson S; Major N; Boonen S; Haentjens P; Mesenbrink P; Magaziner J; Adachi J; Lyles KW; Hyldstrup L; Bucci-Rechtweg C; Recknor C;
Osteoporos Int; 2011 Aug; 22(8):2329-36. PubMed ID: 21153021
[TBL] [Abstract][Full Text] [Related]
4. Zoledronic acid results in better health-related quality of life following hip fracture: the HORIZON-Recurrent Fracture Trial.
Adachi JD; Lyles KW; Colón-Emeric CS; Boonen S; Pieper CF; Mautalen C; Hyldstrup L; Recknor C; Nordsletten L; Moore KA; Bucci-Rechtweg C; Su G; Eriksen EF; Magaziner JS
Osteoporos Int; 2011 Sep; 22(9):2539-49. PubMed ID: 21249332
[TBL] [Abstract][Full Text] [Related]
5. Antifracture efficacy and reduction of mortality in relation to timing of the first dose of zoledronic acid after hip fracture.
Eriksen EF; Lyles KW; Colón-Emeric CS; Pieper CF; Magaziner JS; Adachi JD; Hyldstrup L; Recknor C; Nordsletten L; Lavecchia C; Hu H; Boonen S; Mesenbrink P
J Bone Miner Res; 2009 Jul; 24(7):1308-13. PubMed ID: 19257818
[TBL] [Abstract][Full Text] [Related]
6. Reduction in the risk of clinical fractures after a single dose of zoledronic Acid 5 milligrams.
Reid IR; Black DM; Eastell R; Bucci-Rechtweg C; Su G; Hue TF; Mesenbrink P; Lyles KW; Boonen S;
J Clin Endocrinol Metab; 2013 Feb; 98(2):557-63. PubMed ID: 23293335
[TBL] [Abstract][Full Text] [Related]
7. Effect of once-yearly zoledronic acid five milligrams on fracture risk and change in femoral neck bone mineral density.
Eastell R; Black DM; Boonen S; Adami S; Felsenberg D; Lippuner K; Cummings SR; Delmas PD; Palermo L; Mesenbrink P; Cauley JA;
J Clin Endocrinol Metab; 2009 Sep; 94(9):3215-25. PubMed ID: 19567517
[TBL] [Abstract][Full Text] [Related]
8. The HORIZON Recurrent Fracture Trial: design of a clinical trial in the prevention of subsequent fractures after low trauma hip fracture repair.
Colón-Emeric CS; Caminis J; Suh TT; Pieper CF; Janning C; Magaziner J; Adachi J; Rosario-Jansen T; Mesenbrink P; Horowitz ZD; Lyles KW;
Curr Med Res Opin; 2004 Jun; 20(6):903-10. PubMed ID: 15200749
[TBL] [Abstract][Full Text] [Related]
9. Fracture prevention in patients with cognitive impairment presenting with a hip fracture: secondary analysis of data from the HORIZON Recurrent Fracture Trial.
Prieto-Alhambra D; Judge A; Arden NK; Cooper C; Lyles KW; Javaid MK
Osteoporos Int; 2014 Jan; 25(1):77-83. PubMed ID: 23812596
[TBL] [Abstract][Full Text] [Related]
10. Time to onset of antifracture efficacy and year-by-year persistence of effect of zoledronic acid in women with osteoporosis.
Boonen S; Eastell R; Su G; Mesenbrink P; Cosman F; Cauley JA; Reid IR; Claessens F; Vanderschueren D; Lyles KW; Black DM
J Bone Miner Res; 2012 Jul; 27(7):1487-93. PubMed ID: 22431413
[TBL] [Abstract][Full Text] [Related]
11. Fracture risk and zoledronic acid therapy in men with osteoporosis.
Boonen S; Reginster JY; Kaufman JM; Lippuner K; Zanchetta J; Langdahl B; Rizzoli R; Lipschitz S; Dimai HP; Witvrouw R; Eriksen E; Brixen K; Russo L; Claessens F; Papanastasiou P; Antunez O; Su G; Bucci-Rechtweg C; Hruska J; Incera E; Vanderschueren D; Orwoll E
N Engl J Med; 2012 Nov; 367(18):1714-23. PubMed ID: 23113482
[TBL] [Abstract][Full Text] [Related]
12. Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis.
Black DM; Delmas PD; Eastell R; Reid IR; Boonen S; Cauley JA; Cosman F; Lakatos P; Leung PC; Man Z; Mautalen C; Mesenbrink P; Hu H; Caminis J; Tong K; Rosario-Jansen T; Krasnow J; Hue TF; Sellmeyer D; Eriksen EF; Cummings SR;
N Engl J Med; 2007 May; 356(18):1809-22. PubMed ID: 17476007
[TBL] [Abstract][Full Text] [Related]
13. Review of the cardiovascular safety of zoledronic acid and other bisphosphonates for the treatment of osteoporosis.
John Camm A
Clin Ther; 2010 Mar; 32(3):426-36. PubMed ID: 20399982
[TBL] [Abstract][Full Text] [Related]
14. Once-yearly zoledronic acid in hip fracture prevention.
Demontiero O; Duque G
Clin Interv Aging; 2009; 4():153-64. PubMed ID: 19503777
[TBL] [Abstract][Full Text] [Related]
15. Once-yearly zoledronic acid and days of disability, bed rest, and back pain: randomized, controlled HORIZON Pivotal Fracture Trial.
Cauley JA; Black D; Boonen S; Cummings SR; Mesenbrink P; Palermo L; Man Z; Hadji P; Reid IR;
J Bone Miner Res; 2011 May; 26(5):984-92. PubMed ID: 21542001
[TBL] [Abstract][Full Text] [Related]
16. Zoledronic acid prevents bone loss after liver transplantation: a randomized, double-blind, placebo-controlled trial.
Crawford BA; Kam C; Pavlovic J; Byth K; Handelsman DJ; Angus PW; McCaughan GW
Ann Intern Med; 2006 Feb; 144(4):239-48. PubMed ID: 16490909
[TBL] [Abstract][Full Text] [Related]
17. Clinical risk factors for recurrent fracture after hip fracture: a prospective study.
Colón-Emeric CS; Lyles KW; Su G; Pieper CF; Magaziner JS; Adachi JD; Bucci-Rechtweg CM; Haentjens P; Boonen S;
Calcif Tissue Int; 2011 May; 88(5):425-31. PubMed ID: 21331567
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and Safety of Zoledronic Acid for Treatment of Postmenopausal Osteoporosis: A Meta-Analysis of Randomized Controlled Trials.
Wang C
Am J Ther; 2017; 24(5):e544-e552. PubMed ID: 26938765
[TBL] [Abstract][Full Text] [Related]
19. Zoledronic acid and secondary prevention of fractures.
Calis KA; Pucino F
N Engl J Med; 2007 Nov; 357(18):1861-2. PubMed ID: 17878150
[No Abstract] [Full Text] [Related]
20. Single annual injectable treatment for postmenopausal osteoporosis.
Chapurlat RD
Expert Opin Drug Deliv; 2008 May; 5(5):583-91. PubMed ID: 18491983
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
